Vascular endothelial growth factor gene polymorphisms and risk of primary lung cancer

Su Jeong Lee, Sin Yeob Lee, Hyo Sung Jeon, Sun Ha Park, Jin Sung Jang, Ga Young Lee, Ji Woong Son, Chang Ho Kim, Won Kee Lee, Sin Kam, Rang Woon Park, Tae In Park, Young Mo Kang, In-San Kim, Tae Hoon Jung, Jae Yong Park

Research output: Contribution to journalArticle

116 Citations (Scopus)

Abstract

Angiogenesis is an essential process in the development, growth, and metastasis of malignant tumors including lung cancer. DNA sequence variations in the vascular endothelial growth factor (VEGF) gene may lead to altered VEGF production and/or activity, thereby causing interindividual differences in the susceptibility to lung cancer via their actions on the pathways of tumor angiogenesis. To test this hypothesis, we investigated the potential association between three VEGF polymorphisms (-460T > C, +405C > G, and 936C > T)/haplotypes and the risk of lung cancer in a Korean population. VEGF genotypes were determined in 432 lung cancer patients and 432 healthy controls that were frequency matched for age and sex. VEGF haplotypes were predicted using Bayesian algorithm in the phase program. Compared with the combined +405 CC and CG genotype, the +405 GG genotype found associated with a significantly decreased risk of small cell carcinoma [SCC; adjusted odds ratio (OR), 0.36; 95% confidence interval (95% CI), 0.17-0.78]. The 936 CT genotype and the combined 936 CT and TT genotype were also associated with a significantly decreased risk of SCC compared with the 936 CC genotype (adjusted OR, 0.47; 95% CI, 0.26-0.85 and adjusted OR, 0.44; 95% CI, 0.24-0.80, respectively). Haplotype CGT was associated with a significantly decreased risk of SCC (adjusted OR, 0.39; 95% CI, 0.18-0.87), whereas haplotype TCC conferred a significantly increased risk of SCC (adjusted OR, 1.63; 95% CI, 1.14-2.33). None of the VEGF polymorphisms studied significantly influenced the susceptibility to lung cancer except SCC. However, haplotypes TCT and TGT were significantly associated with the risk of overall lung cancer, respectively (adjusted OR, 0.38; 95% CI, 0.25-0.60 and adjusted OR, 3.94; 95% CI, 2.00-7.76, respectively). These effects of haplotypes TCT and TGT on lung cancer risk were observed in three major histologic types of lung cancer. These results suggest that the VEGF gene may be contribute to an inherited predisposition to lung cancer.

Original languageEnglish
Pages (from-to)571-575
Number of pages5
JournalCancer Epidemiology Biomarkers and Prevention
Volume14
Issue number3
DOIs
Publication statusPublished - 2005 Mar 1
Externally publishedYes

Fingerprint

Vascular Endothelial Growth Factor A
Lung Neoplasms
Haplotypes
Odds Ratio
Confidence Intervals
Genotype
Genes
Small Cell Carcinoma
Growth and Development
Neoplasms
Neoplasm Metastasis
Population

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Lee, S. J., Lee, S. Y., Jeon, H. S., Park, S. H., Jang, J. S., Lee, G. Y., ... Park, J. Y. (2005). Vascular endothelial growth factor gene polymorphisms and risk of primary lung cancer. Cancer Epidemiology Biomarkers and Prevention, 14(3), 571-575. https://doi.org/10.1158/1055-9965.EPI-04-0472

Vascular endothelial growth factor gene polymorphisms and risk of primary lung cancer. / Lee, Su Jeong; Lee, Sin Yeob; Jeon, Hyo Sung; Park, Sun Ha; Jang, Jin Sung; Lee, Ga Young; Son, Ji Woong; Kim, Chang Ho; Lee, Won Kee; Kam, Sin; Park, Rang Woon; Park, Tae In; Kang, Young Mo; Kim, In-San; Jung, Tae Hoon; Park, Jae Yong.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 14, No. 3, 01.03.2005, p. 571-575.

Research output: Contribution to journalArticle

Lee, SJ, Lee, SY, Jeon, HS, Park, SH, Jang, JS, Lee, GY, Son, JW, Kim, CH, Lee, WK, Kam, S, Park, RW, Park, TI, Kang, YM, Kim, I-S, Jung, TH & Park, JY 2005, 'Vascular endothelial growth factor gene polymorphisms and risk of primary lung cancer', Cancer Epidemiology Biomarkers and Prevention, vol. 14, no. 3, pp. 571-575. https://doi.org/10.1158/1055-9965.EPI-04-0472
Lee, Su Jeong ; Lee, Sin Yeob ; Jeon, Hyo Sung ; Park, Sun Ha ; Jang, Jin Sung ; Lee, Ga Young ; Son, Ji Woong ; Kim, Chang Ho ; Lee, Won Kee ; Kam, Sin ; Park, Rang Woon ; Park, Tae In ; Kang, Young Mo ; Kim, In-San ; Jung, Tae Hoon ; Park, Jae Yong. / Vascular endothelial growth factor gene polymorphisms and risk of primary lung cancer. In: Cancer Epidemiology Biomarkers and Prevention. 2005 ; Vol. 14, No. 3. pp. 571-575.
@article{0106662642a0467884d8e4f8147a71b5,
title = "Vascular endothelial growth factor gene polymorphisms and risk of primary lung cancer",
abstract = "Angiogenesis is an essential process in the development, growth, and metastasis of malignant tumors including lung cancer. DNA sequence variations in the vascular endothelial growth factor (VEGF) gene may lead to altered VEGF production and/or activity, thereby causing interindividual differences in the susceptibility to lung cancer via their actions on the pathways of tumor angiogenesis. To test this hypothesis, we investigated the potential association between three VEGF polymorphisms (-460T > C, +405C > G, and 936C > T)/haplotypes and the risk of lung cancer in a Korean population. VEGF genotypes were determined in 432 lung cancer patients and 432 healthy controls that were frequency matched for age and sex. VEGF haplotypes were predicted using Bayesian algorithm in the phase program. Compared with the combined +405 CC and CG genotype, the +405 GG genotype found associated with a significantly decreased risk of small cell carcinoma [SCC; adjusted odds ratio (OR), 0.36; 95{\%} confidence interval (95{\%} CI), 0.17-0.78]. The 936 CT genotype and the combined 936 CT and TT genotype were also associated with a significantly decreased risk of SCC compared with the 936 CC genotype (adjusted OR, 0.47; 95{\%} CI, 0.26-0.85 and adjusted OR, 0.44; 95{\%} CI, 0.24-0.80, respectively). Haplotype CGT was associated with a significantly decreased risk of SCC (adjusted OR, 0.39; 95{\%} CI, 0.18-0.87), whereas haplotype TCC conferred a significantly increased risk of SCC (adjusted OR, 1.63; 95{\%} CI, 1.14-2.33). None of the VEGF polymorphisms studied significantly influenced the susceptibility to lung cancer except SCC. However, haplotypes TCT and TGT were significantly associated with the risk of overall lung cancer, respectively (adjusted OR, 0.38; 95{\%} CI, 0.25-0.60 and adjusted OR, 3.94; 95{\%} CI, 2.00-7.76, respectively). These effects of haplotypes TCT and TGT on lung cancer risk were observed in three major histologic types of lung cancer. These results suggest that the VEGF gene may be contribute to an inherited predisposition to lung cancer.",
author = "Lee, {Su Jeong} and Lee, {Sin Yeob} and Jeon, {Hyo Sung} and Park, {Sun Ha} and Jang, {Jin Sung} and Lee, {Ga Young} and Son, {Ji Woong} and Kim, {Chang Ho} and Lee, {Won Kee} and Sin Kam and Park, {Rang Woon} and Park, {Tae In} and Kang, {Young Mo} and In-San Kim and Jung, {Tae Hoon} and Park, {Jae Yong}",
year = "2005",
month = "3",
day = "1",
doi = "10.1158/1055-9965.EPI-04-0472",
language = "English",
volume = "14",
pages = "571--575",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Vascular endothelial growth factor gene polymorphisms and risk of primary lung cancer

AU - Lee, Su Jeong

AU - Lee, Sin Yeob

AU - Jeon, Hyo Sung

AU - Park, Sun Ha

AU - Jang, Jin Sung

AU - Lee, Ga Young

AU - Son, Ji Woong

AU - Kim, Chang Ho

AU - Lee, Won Kee

AU - Kam, Sin

AU - Park, Rang Woon

AU - Park, Tae In

AU - Kang, Young Mo

AU - Kim, In-San

AU - Jung, Tae Hoon

AU - Park, Jae Yong

PY - 2005/3/1

Y1 - 2005/3/1

N2 - Angiogenesis is an essential process in the development, growth, and metastasis of malignant tumors including lung cancer. DNA sequence variations in the vascular endothelial growth factor (VEGF) gene may lead to altered VEGF production and/or activity, thereby causing interindividual differences in the susceptibility to lung cancer via their actions on the pathways of tumor angiogenesis. To test this hypothesis, we investigated the potential association between three VEGF polymorphisms (-460T > C, +405C > G, and 936C > T)/haplotypes and the risk of lung cancer in a Korean population. VEGF genotypes were determined in 432 lung cancer patients and 432 healthy controls that were frequency matched for age and sex. VEGF haplotypes were predicted using Bayesian algorithm in the phase program. Compared with the combined +405 CC and CG genotype, the +405 GG genotype found associated with a significantly decreased risk of small cell carcinoma [SCC; adjusted odds ratio (OR), 0.36; 95% confidence interval (95% CI), 0.17-0.78]. The 936 CT genotype and the combined 936 CT and TT genotype were also associated with a significantly decreased risk of SCC compared with the 936 CC genotype (adjusted OR, 0.47; 95% CI, 0.26-0.85 and adjusted OR, 0.44; 95% CI, 0.24-0.80, respectively). Haplotype CGT was associated with a significantly decreased risk of SCC (adjusted OR, 0.39; 95% CI, 0.18-0.87), whereas haplotype TCC conferred a significantly increased risk of SCC (adjusted OR, 1.63; 95% CI, 1.14-2.33). None of the VEGF polymorphisms studied significantly influenced the susceptibility to lung cancer except SCC. However, haplotypes TCT and TGT were significantly associated with the risk of overall lung cancer, respectively (adjusted OR, 0.38; 95% CI, 0.25-0.60 and adjusted OR, 3.94; 95% CI, 2.00-7.76, respectively). These effects of haplotypes TCT and TGT on lung cancer risk were observed in three major histologic types of lung cancer. These results suggest that the VEGF gene may be contribute to an inherited predisposition to lung cancer.

AB - Angiogenesis is an essential process in the development, growth, and metastasis of malignant tumors including lung cancer. DNA sequence variations in the vascular endothelial growth factor (VEGF) gene may lead to altered VEGF production and/or activity, thereby causing interindividual differences in the susceptibility to lung cancer via their actions on the pathways of tumor angiogenesis. To test this hypothesis, we investigated the potential association between three VEGF polymorphisms (-460T > C, +405C > G, and 936C > T)/haplotypes and the risk of lung cancer in a Korean population. VEGF genotypes were determined in 432 lung cancer patients and 432 healthy controls that were frequency matched for age and sex. VEGF haplotypes were predicted using Bayesian algorithm in the phase program. Compared with the combined +405 CC and CG genotype, the +405 GG genotype found associated with a significantly decreased risk of small cell carcinoma [SCC; adjusted odds ratio (OR), 0.36; 95% confidence interval (95% CI), 0.17-0.78]. The 936 CT genotype and the combined 936 CT and TT genotype were also associated with a significantly decreased risk of SCC compared with the 936 CC genotype (adjusted OR, 0.47; 95% CI, 0.26-0.85 and adjusted OR, 0.44; 95% CI, 0.24-0.80, respectively). Haplotype CGT was associated with a significantly decreased risk of SCC (adjusted OR, 0.39; 95% CI, 0.18-0.87), whereas haplotype TCC conferred a significantly increased risk of SCC (adjusted OR, 1.63; 95% CI, 1.14-2.33). None of the VEGF polymorphisms studied significantly influenced the susceptibility to lung cancer except SCC. However, haplotypes TCT and TGT were significantly associated with the risk of overall lung cancer, respectively (adjusted OR, 0.38; 95% CI, 0.25-0.60 and adjusted OR, 3.94; 95% CI, 2.00-7.76, respectively). These effects of haplotypes TCT and TGT on lung cancer risk were observed in three major histologic types of lung cancer. These results suggest that the VEGF gene may be contribute to an inherited predisposition to lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=20144387124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20144387124&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-04-0472

DO - 10.1158/1055-9965.EPI-04-0472

M3 - Article

C2 - 15767331

AN - SCOPUS:20144387124

VL - 14

SP - 571

EP - 575

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 3

ER -